PRESS RELEASE published on 09/21/2026 at 19:00, 1 month 23 days ago Inside Information / Other news releases MaaT Pharma announces Pre-IND meeting with FDA for MaaT034 clinical development in solid tumors. Company advances microbiome therapies for cancer patients through immune modulation FDA MaaT Pharma Pre-IND Meeting MaaT034 Microbiome Therapies
BRIEF published on 09/18/2026 at 07:35, 1 month 27 days ago MaaT Pharma fait face à un revers suite à la décision du CHMP concernant MaaT013 Essai Clinique MaaT013 Décision Du CHMP Étude PHOENIX Plan Réglementaire
BRIEF published on 09/18/2026 at 07:35, 1 month 27 days ago MaaT Pharma Faces Setback with CHMP Decision on MaaT013 Clinical Trial MaaT013 CHMP Decision PHOENIX Study Regulatory Plan
PRESS RELEASE published on 09/18/2026 at 07:30, 1 month 27 days ago Informations privilégiées / Autres communiqués MaaT Pharma annonce l'opinion négative du CHMP sur MaaT013 (Xervyteg®) et le plan de développement de l'essai clinique PHOENIX aux États-Unis et en Europe Phoenix Essai Clinique MaaT Pharma CHMP MaaT013
PRESS RELEASE published on 09/18/2026 at 07:30, 1 month 27 days ago Inside Information / Other news releases MaaT Pharma provides update on CHMP negative opinion for MaaT013 (Xervyteg) development plan, focusing on Phase 3 trial PHOENIX. FDA support noted for potential patient enrollment in H1 2027 FDA Phase 3 Trial MaaT Pharma CHMP MaaT013
BRIEF published on 09/15/2026 at 07:35, 2 months ago MaaT Pharma : vote défavorable du CHMP pour MaaT013 MaaT Pharma CHMP MaaT013 Essai Randomisé Vote Négatif
BRIEF published on 09/15/2026 at 07:35, 2 months ago MaaT Pharma: unfavorable vote by the CHMP for MaaT013 MaaT Pharma MaaT013 CHAMP Negative Vote Randomized Trial
PRESS RELEASE published on 09/15/2026 at 07:30, 2 months ago Inside Information / Other news releases MaaT Pharma receives negative CHMP trend vote for MaaT013 (Xervyteg) conditional marketing authorization application in Europe. Company vows to explore options for patient access MaaT Pharma CHMP Clinical Benefit Xervyteg Negative Trend
PRESS RELEASE published on 09/15/2026 at 07:30, 2 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce une tendance négative du CHMP pour MaaT013 (Xervyteg®) en Europe. Retour oral révéle préoccupations sur bénéfice clinique et sécurité MaaT Pharma CHMP MaaT013 Xervyteg® Tendance Négative
BRIEF published on 07/24/2026 at 12:17, 3 months 21 days ago Invus Public Equities réduit sa participation dans MAAT PHARMA Droits De Vote Franchissement De Seuil Cession D'actions MaaT Pharma Invus
Published on 11/14/2026 at 12:56, 23 hours 17 minutes ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 10 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 11 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 11 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 12 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 12 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 14 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 17 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 17 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 4 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 13 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
